{
    "clinical_study": {
        "@rank": "134527", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 (Itraconazole DDI)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2 (Fluoxetine DDI)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, open-label, one-sequence, 2-period, within-subject study in 2 cohorts\n      will evaluate the effects of multiple doses of itraconazole and fluoxetine on the\n      pharmacokinetics of a single dose of RO5285119 in healthy volunteers. In Cohort 1, subjects\n      will receive a single dose of RO5285119 on Day 1 (Period 1) and, after a wash-out period of\n      14 days, itraconazole on Days 1-8 of Period 2 with coadministration of RO5285119 on Day 4.\n      In Cohort 2, subjects will receive a single dose of RO5285119 on Day 1 (Period 1) and, after\n      a wash-out period of 14 days, fluoxetine on Days 1-12 of Period 2 with coadministration of\n      RO5285119 on Day 6."
        }, 
        "brief_title": "A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female subjects, 18 to 55 years of age, inclusive. Healthy status is\n             defined by absence of evidence of any active or chronic disease following a detailed\n             medical and surgical history, and a complete physical examination\n\n          -  Body mass index (BMI) between 18 to 30 kg/m2 inclusive\n\n          -  Women must be postmenopausal (for at least 12 months of amenorrhea confirmed by FSH,\n             or for at least 24 months if on hormone replacement therapy) or surgically sterile\n             (absence of ovaries and/or uterus)\n\n          -  For men with a female partner of child-bearing potential: agreement to use a barrier\n             method of contraception during the treatment period and for at least 3 months after\n             the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Suspicion of regular consumption of drug of abuse, or history of drug or alcohol\n             abuse\n\n          -  Positive for hepatitis B, hepatitis C , or HIV infection\n\n          -  Participation in an investigational drug or device study within 90 days prior to\n             first dosing\n\n          -  Concomitant disease or condition that could interfere with, or treatment of which\n             might interfere with, the conduct of the study, or that would, in the opinion of the\n             investigator, pose an unacceptable risk to the subject in this study\n\n          -  Hypersensitivity to itraconazole, to any of the other ingredients, or to any other\n             triazole antifungal, or any other known contraindications to itraconazole as stated\n             in the SmPC\n\n          -  Hypersensitivity to fluoxetine or to any of the other ingredients, or any other known\n             contraindications to fluoxetine as stated in the SmPC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967979", 
            "org_study_id": "BP28977", 
            "secondary_id": "2013-003232-76"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 (Itraconazole DDI)", 
                    "Cohort 2 (Fluoxetine DDI)"
                ], 
                "description": "Single dose, alone and after repeated administration of itraconazole or fluoxetine", 
                "intervention_name": "RO5285119", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1 (Itraconazole DDI)", 
                "description": "Multiple doses", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2 (Fluoxetine DDI)", 
                "description": "Multiple doses", 
                "intervention_name": "fluoxetine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluoxetine", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Open-Label, One-Sequence, 2-Period, Within-Subject Study in 2 Cohorts to Investigate the Effect of Multiple Doses of Itraconazole (Cohort 1) and Fluoxetine (Cohort 2) on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands:Centrale Commissie Mensgebonden Onderzoek"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Effect of multiple doses of itraconazole and fluoxetine on the pharmacokinetics of a single dose of RO5285119 in healthy volunteers: Maximum concentration (Cmax) / Area under the concentration-time curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "up to 5 and 7 days post-dose for cohort 1 and cohort 2, respectively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967979"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety and tolerability of a single dose of RO5285119 administered in combination with itraconazole (cohort 1) and fluoxetine (cohort 2): Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}